Latest Health News

Region Group announces a 6.9 cent per stapled security distribution for H1 FY26 and confirms its AFFO guidance of 14.0 cents per security for the full year.

Central Iron Ore Limited has announced a rights offering to raise up to $2.89 million, aiming to support its South Darlot joint venture, advance drilling at British King Mine, and repay a loan to majority shareholder Gullewa Limited.

Wellnex Life reports encouraging early results from its turnaround strategy, posting a modest EBITDA profit and robust sales growth for its Pain Away brand.

CONNEQT Health’s Pulse arterial health monitor sales have outpaced expectations with over 200% growth in the December quarter, driven by efficient marketing and early subscription uptake.

Recce Pharmaceuticals has won a significant Australian Government R&D tax incentive, unlocking up to A$85 million for its synthetic anti-infective programs worldwide, including a pivotal Phase 3 clinical trial.

Bank of Queensland Limited has announced a fully franked quarterly distribution of AUD 1.2412 per Capital Note 3 security, payable in March 2026. The distribution reflects a 4.9784% annualised rate based on the BBSW plus a margin.

Emyria has secured its first Empax clinic in Victoria, marking a significant step in its multi-state expansion and validating its scalable, reimbursed national mental health platform.

Fiducian Group’s subsidiary Fiducian Investment Management Services Limited has filed a defence after ASIC initiated civil proceedings alleging misleading disclosure and compliance failures related to a managed fund.

CTI Logistics Limited anticipates a significant 55% increase in profit before tax for the half year ending December 2025, driven by robust revenue growth and operational improvements in Western Australia.

4DMedical has gained Canadian regulatory approval for its innovative CT – VQ™ ventilation-perfusion imaging technology, enabling immediate commercial rollout through Philips and expanding its North American footprint.

Orthocell has lodged a regulatory application to distribute its nerve repair product Remplir™ across the EU and UK, aiming to tap into a $750 million market with approval expected by Q3 2026.

Imricor Medical Systems has secured Institutional Review Board approval for the University of Virginia Health to join its VISABL-AFL clinical trial, marking a key expansion in the US. Procedures are set to begin early next year, supporting Imricor’s progress toward FDA approval and commercialisation.